Whitehawk Therapeutics (WHWK)
Market Price (7/17/2026): $3.86 | Market Cap: $267.3 MilSector: Health Care | Industry: Biotechnology
Whitehawk Therapeutics (WHWK)
Market Price (7/17/2026): $3.86Market Cap: $267.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -46% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -123 Mil Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -19%, Rev Chg QQuarterly Revenue Change % is null Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -47% Key risksWHWK key risks include [1] reliance on successfully advancing its preclinical drug pipeline, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -46% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -123 Mil |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -19%, Rev Chg QQuarterly Revenue Change % is null |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -47% |
| Key risksWHWK key risks include [1] reliance on successfully advancing its preclinical drug pipeline, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/13/2026
Whitehawk Therapeutics (WHWK) stock has gained about 15% since 3/31/2026 because of the following key factors:
1. Whitehawk Therapeutics reported strong fiscal Q1 2026 earnings, surpassing analyst expectations. The company announced an earnings per share (EPS) loss of $0.32 for the quarter ended March 31, 2026, which exceeded the consensus estimate of a $0.36 loss by 12.11%. This positive surprise on May 7, 2026, was met with investor optimism, leading to a 6.24% increase in the stock price on the announcement date.
2. The company secured substantial funding through a private placement equity financing in May 2026. Whitehawk Therapeutics successfully closed an $87.5 million private investment in public equity (PIPE) financing, which included participation from existing investors. This capital infusion is projected to extend the company's cash runway into the second half of 2028, providing critical resources to advance its Antibody-Drug Conjugate (ADC) pipeline and related development activities.
Show more
Whitehawk Therapeutics (WHWK) stock has gained about 15% since 3/31/2026 because of the following key factors:
1. Whitehawk Therapeutics reported strong fiscal Q1 2026 earnings, surpassing analyst expectations. The company announced an earnings per share (EPS) loss of $0.32 for the quarter ended March 31, 2026, which exceeded the consensus estimate of a $0.36 loss by 12.11%. This positive surprise on May 7, 2026, was met with investor optimism, leading to a 6.24% increase in the stock price on the announcement date.
2. The company secured substantial funding through a private placement equity financing in May 2026. Whitehawk Therapeutics successfully closed an $87.5 million private investment in public equity (PIPE) financing, which included participation from existing investors. This capital infusion is projected to extend the company's cash runway into the second half of 2028, providing critical resources to advance its Antibody-Drug Conjugate (ADC) pipeline and related development activities.
Show more
Updated on 7/13/2026
Whitehawk Therapeutics (WHWK) stock has gained about 15% since 3/31/2026 because of the following key factors:
1. Whitehawk Therapeutics reported strong fiscal Q1 2026 earnings, surpassing analyst expectations. The company announced an earnings per share (EPS) loss of $0.32 for the quarter ended March 31, 2026, which exceeded the consensus estimate of a $0.36 loss by 12.11%. This positive surprise on May 7, 2026, was met with investor optimism, leading to a 6.24% increase in the stock price on the announcement date.
2. The company secured substantial funding through a private placement equity financing in May 2026. Whitehawk Therapeutics successfully closed an $87.5 million private investment in public equity (PIPE) financing, which included participation from existing investors. This capital infusion is projected to extend the company's cash runway into the second half of 2028, providing critical resources to advance its Antibody-Drug Conjugate (ADC) pipeline and related development activities.
3. Positive preclinical data and ongoing clinical trial progress for its ADC pipeline bolstered investor confidence. Whitehawk Therapeutics presented comprehensive preclinical data for its next-generation ADC portfolio (HWK-007, HWK-016, and HWK-206) at the American Association for Cancer Research (AACR) Annual Meeting in April 2026. These data highlighted potent tumor regressions, high plasma stability, and favorable tolerability, supported by a proprietary linker-payload technology. Furthermore, Phase 1 trials for HWK-007 and HWK-016 are actively enrolling patients, and an Investigational New Drug (IND) submission for HWK-206 is on track for mid-2026, with a Phase 1 clinical trial initiation planned for fiscal Q3 2026. The company also presented data confirming MUC16 and SEZ6 as highly expressed and clinically relevant targets for various cancers at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting and ASCO 2026, respectively.
4. Favorable analyst coverage and increased price targets contributed to the positive trend. In July 2026, Leerink Partners initiated coverage on Whitehawk Therapeutics with an "Outperform" rating and set a price target of $9.00, suggesting a potential upside of 126.70% from the stock's then-current price. This followed an "Outperform" rating from Citigroup in April 2026, contributing to an overall "Moderate Buy" consensus rating from analysts, with an average price target of $8.00.
Show less
Whitehawk Therapeutics (WHWK) stock has gained about 15% since 3/31/2026 because of the following key factors:
1. Whitehawk Therapeutics reported strong fiscal Q1 2026 earnings, surpassing analyst expectations. The company announced an earnings per share (EPS) loss of $0.32 for the quarter ended March 31, 2026, which exceeded the consensus estimate of a $0.36 loss by 12.11%. This positive surprise on May 7, 2026, was met with investor optimism, leading to a 6.24% increase in the stock price on the announcement date.
2. The company secured substantial funding through a private placement equity financing in May 2026. Whitehawk Therapeutics successfully closed an $87.5 million private investment in public equity (PIPE) financing, which included participation from existing investors. This capital infusion is projected to extend the company's cash runway into the second half of 2028, providing critical resources to advance its Antibody-Drug Conjugate (ADC) pipeline and related development activities.
3. Positive preclinical data and ongoing clinical trial progress for its ADC pipeline bolstered investor confidence. Whitehawk Therapeutics presented comprehensive preclinical data for its next-generation ADC portfolio (HWK-007, HWK-016, and HWK-206) at the American Association for Cancer Research (AACR) Annual Meeting in April 2026. These data highlighted potent tumor regressions, high plasma stability, and favorable tolerability, supported by a proprietary linker-payload technology. Furthermore, Phase 1 trials for HWK-007 and HWK-016 are actively enrolling patients, and an Investigational New Drug (IND) submission for HWK-206 is on track for mid-2026, with a Phase 1 clinical trial initiation planned for fiscal Q3 2026. The company also presented data confirming MUC16 and SEZ6 as highly expressed and clinically relevant targets for various cancers at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting and ASCO 2026, respectively.
4. Favorable analyst coverage and increased price targets contributed to the positive trend. In July 2026, Leerink Partners initiated coverage on Whitehawk Therapeutics with an "Outperform" rating and set a price target of $9.00, suggesting a potential upside of 126.70% from the stock's then-current price. This followed an "Outperform" rating from Citigroup in April 2026, contributing to an overall "Moderate Buy" consensus rating from analysts, with an average price target of $8.00.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 12.8% change in WHWK stock from 3/31/2026 to 7/16/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 7162026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.45 | 3.89 | 12.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 0 | |
| P/S Multiple | 33.5 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 69 | 69 | 0.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2026 to 7/16/2026| Return | Correlation | |
|---|---|---|
| WHWK | 12.8% | |
| Market (SPY) | 15.4% | 27.4% |
| Sector (XLV) | 10.4% | 11.7% |
Fundamental Drivers
The 60.7% change in WHWK stock from 12/31/2025 to 7/16/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 7162026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.42 | 3.89 | 60.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14 | 0 | |
| P/S Multiple | 11.6 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 69 | 69 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 7/16/2026| Return | Correlation | |
|---|---|---|
| WHWK | 60.7% | |
| Market (SPY) | 10.4% | 24.1% |
| Sector (XLV) | 5.0% | 14.9% |
Fundamental Drivers
The 108.0% change in WHWK stock from 6/30/2025 to 7/16/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 6302025 | 7162026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.87 | 3.89 | 108.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 28 | 0 | |
| P/S Multiple | 2.7 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 40 | 69 | -42.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2025 to 7/16/2026| Return | Correlation | |
|---|---|---|
| WHWK | 108.0% | |
| Market (SPY) | 22.5% | 25.7% |
| Sector (XLV) | 21.6% | 16.1% |
Fundamental Drivers
nullnull
Market Drivers
6/30/2023 to 7/16/2026| Return | Correlation | |
|---|---|---|
| WHWK | ||
| Market (SPY) | 75.3% | 21.5% |
| Sector (XLV) | 27.6% | 14.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| WHWK Return | - | - | - | - | 20% | 59% | 91% |
| Peers Return | -50% | -63% | -18% | -16% | 77% | 4% | -77% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| WHWK Win Rate | - | - | - | - | 60% | 57% | |
| Peers Win Rate | 35% | 37% | 45% | 43% | 48% | 54% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| WHWK Max Drawdown | - | - | - | - | - | -25% | |
| Peers Max Drawdown | -56% | -77% | -65% | -64% | -57% | -49% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ADCT, STRO, BOLT, ZYME, CTMX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/16/2026 (YTD)
How Low Can It Go
WHWK has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
WHWK has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Whitehawk Therapeutics (WHWK)
Whitehawk Therapeutics (WHWK) is a clinical-stage biopharmaceutical company focused on developing and commercializing precision therapies for specific types of cancer. The company specializes in addressing genetically defined cancers that have alterations in mTOR pathway genes. By targeting these specific genetic markers, Whitehawk aims to provide more precise and effective treatment options for patients.
The company's primary product and lead drug candidate is FYARRO, which is a unique formulation of sirolimus bound to albumin. FYARRO is currently undergoing evaluation for its efficacy in treating various cancers. This includes cancers with known mTOR pathway activation, as well as tumor-agnostic indications that target specific genomic alterations responsible for activating the mTOR pathway.
Whitehawk Therapeutics serves the oncology market, with a focus on patients suffering from genetically defined cancers. Its primary customers are those with cancers exhibiting mTOR pathway gene alterations, offering a specialized approach to cancer treatment based on a deep understanding of genetic pathways involved in disease progression.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
Whitehawk Therapeutics (symbol: WHWK), which operates as Aadi Bioscience, Inc., is a clinical-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers, including its lead drug candidate FYARRO. As a pharmaceutical manufacturer, the company's primary customers are other companies within the healthcare supply chain rather than individual patients directly.
Its major customers typically include:
- Pharmaceutical Wholesalers: These large distributors purchase drugs directly from manufacturers and subsequently distribute them to hospitals, pharmacies, and other healthcare providers. Key players in this sector that frequently serve as major customers for pharmaceutical companies include:
- Hospitals and Cancer Treatment Centers: These healthcare institutions administer specialized drugs like FYARRO to patients as part of their inpatient or outpatient treatment regimens.
- Specialty Pharmacies: Given the complex nature, specific handling requirements, and high cost often associated with oncology drugs, Aadi Bioscience may also sell to or partner with specialty pharmacies that focus on dispensing and providing support for such medications.
AI Analysis | Feedback
- Accord BioPharma, Inc.
- Lonza Group Ltd (LONN)
AI Analysis | Feedback
null
AI Analysis | Feedback
The key risks to Whitehawk Therapeutics (WHWK), a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs), primarily revolve around the inherent challenges of drug development in the oncology sector.
- Clinical Development and Regulatory Risks: As a clinical-stage company, Whitehawk Therapeutics faces significant uncertainties in the development and approval of its ADC portfolio. Risks include potential delays in the commencement, enrollment, and completion of clinical trials, as well as the possibility of failing to demonstrate the efficacy of its ADC assets in preclinical and clinical studies. There is also the risk of unforeseen adverse reactions or side effects occurring during testing. Regulatory bodies, such as the U.S. FDA, maintain stringent standards for ADC safety, efficacy, and quality control, demanding substantial improvements in patient survival or quality of life for drug approval.
- Manufacturing Complexity and High Costs: The development and production of ADCs are complex, multi-step processes involving antibody production, drug synthesis, and conjugation reactions. This complexity elevates the risk of product loss, contamination, and drives higher production costs. The overall expense associated with developing and manufacturing ADC therapies can be a barrier to profitability, and the high cost of ADC treatment regimens themselves can limit market access.
- Competition and Intellectual Property Risks: Whitehawk Therapeutics operates within a highly competitive oncology and ADC market. Successfully bringing an ADC to market requires not only demonstrating efficacy and safety but also navigating a crowded landscape of existing and pipeline therapies. Furthermore, the company must effectively manage complex intellectual property issues, including patenting its antibodies, linkers, and cytotoxic agents, to avoid infringement and protect its proprietary technologies.
AI Analysis | Feedback
null
AI Analysis | Feedback
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), formerly known as Aadi Bioscience, Inc., has undergone a strategic transformation. The company divested its FYARRO business to KAKEN Pharmaceutical and is now focused on developing a portfolio of antibody-drug conjugates (ADCs).
The main products for Whitehawk Therapeutics are now its three preclinical ADC programs, HWK-007, HWK-016, and HWK-206, which are being developed for various cancers, including lung and ovarian cancers and neuroendocrine tumors.
Information regarding the specific addressable market sizes for Whitehawk Therapeutics' current ADC product pipeline in lung, ovarian, and neuroendocrine cancers is not readily available in the provided search results. Therefore, the addressable markets for their main products or services cannot be sized based on the provided information.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Whitehawk Therapeutics Earnings Notes | 12/16/2025 | |
| Is Whitehawk Therapeutics Stock Built to Withstand a Pullback? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 4.04 |
| Mkt Cap | 0.3 |
| Rev LTM | 57 |
| Op Inc LTM | -96 |
| FCF LTM | -94 |
| FCF 3Y Avg | -81 |
| CFO LTM | -94 |
| CFO 3Y Avg | -79 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -4.3% |
| Rev Chg 3Y Avg | 1.3% |
| Rev Chg Q | -85.5% |
| QoQ Delta Rev Chg LTM | -19.4% |
| Op Inc Chg LTM | 5.2% |
| Op Inc Chg 3Y Avg | -2.9% |
| Op Mgn LTM | -140.2% |
| Op Mgn 3Y Avg | -170.7% |
| QoQ Delta Op Mgn LTM | -13.4% |
| CFO/Rev LTM | -152.2% |
| CFO/Rev 3Y Avg | -173.4% |
| FCF/Rev LTM | -152.7% |
| FCF/Rev 3Y Avg | -176.3% |
Price Behavior
Price Behavior
| Market Price | $3.89 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 08/08/2017 | |
| Distance from 52W High | -23.7% | |
| 50 Days | 200 Days | |
| DMA Price | $4.21 | $2.02 |
| DMA Trend | up | up |
| Distance from DMA | -7.5% | 93.0% |
| 3M | 1YR | |
| Volatility | 78.2% | 78.7% |
| Downside Capture | 204.25 | 109.62 |
| Upside Capture | 109.41 | 166.33 |
| Correlation (SPY) | 25.8% | 26.3% |
WHWK Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.24 | 2.02 | 1.73 | 1.35 | 1.63 | 0.41 |
| Up Beta | 3.89 | 2.43 | 1.33 | 1.88 | 2.27 | 0.09 |
| Down Beta | 3.59 | 2.26 | 1.85 | 1.80 | 1.65 | 0.22 |
| Up Capture | -49% | 216% | 223% | 175% | 256% | 38% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 13 | 24 | 33 | 64 | 127 | 159 |
| Down Capture | -15% | 148% | 171% | 41% | 98% | 73% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 8 | 16 | 29 | 56 | 112 | 147 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with WHWK | |
|---|---|---|---|---|
| WHWK | 101.1% | 78.5% | 1.21 | - |
| Sector ETF (XLV) | 23.7% | 15.9% | 1.15 | 16.2% |
| Equity (SPY) | 21.8% | 12.6% | 1.29 | 26.0% |
| Gold (GLD) | 19.1% | 28.0% | 0.61 | 11.0% |
| Commodities (DBC) | 27.9% | 18.9% | 1.16 | -5.1% |
| Real Estate (VNQ) | 16.9% | 14.0% | 0.88 | 11.0% |
| Bitcoin (BTCUSD) | -45.3% | 42.8% | -1.29 | 13.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with WHWK | |
|---|---|---|---|---|
| WHWK | 12.8% | 75.2% | 0.92 | - |
| Sector ETF (XLV) | 6.4% | 15.0% | 0.24 | 14.8% |
| Equity (SPY) | 13.2% | 17.1% | 0.60 | 21.8% |
| Gold (GLD) | 16.7% | 18.4% | 0.73 | 5.8% |
| Commodities (DBC) | 8.5% | 19.5% | 0.33 | -0.8% |
| Real Estate (VNQ) | 3.2% | 18.9% | 0.07 | 13.4% |
| Bitcoin (BTCUSD) | 14.5% | 53.5% | 0.45 | 15.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with WHWK | |
|---|---|---|---|---|
| WHWK | 6.2% | 75.2% | 0.92 | - |
| Sector ETF (XLV) | 10.1% | 16.6% | 0.49 | 14.8% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 21.8% |
| Gold (GLD) | 10.9% | 16.1% | 0.55 | 5.8% |
| Commodities (DBC) | 6.5% | 18.0% | 0.28 | -0.8% |
| Real Estate (VNQ) | 5.2% | 20.7% | 0.22 | 13.4% |
| Bitcoin (BTCUSD) | 57.8% | 66.2% | 0.98 | 15.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/12/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | -5.1% | 18.8% | 0.0% |
| 3/12/2026 | -2.7% | -5.0% | -15.5% |
| 11/6/2025 | -6.7% | -0.9% | 6.2% |
| 8/7/2025 | -4.4% | -5.0% | 1.1% |
| 5/8/2025 | 3.7% | 3.0% | 19.5% |
| SUMMARY STATS | |||
| # Positive | 1 | 2 | 4 |
| # Negative | 4 | 3 | 1 |
| Median Positive | 3.7% | 10.9% | 3.7% |
| Median Negative | -4.8% | -5.0% | -15.5% |
| Max Positive | 3.7% | 18.8% | 19.5% |
| Max Negative | -6.7% | -5.0% | -15.5% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | -5.1% | 18.8% | 0.0% |
| 3/12/2026 | -2.7% | -5.0% | -15.5% |
| 11/6/2025 | -6.7% | -0.9% | 6.2% |
| 8/7/2025 | -4.4% | -5.0% | 1.1% |
| 5/8/2025 | 3.7% | 3.0% | 19.5% |
| SUMMARY STATS | |||
| # Positive | 1 | 2 | 4 |
| # Negative | 4 | 3 | 1 |
| Median Positive | 3.7% | 10.9% | 3.7% |
| Median Negative | -4.8% | -5.0% | -15.5% |
| Max Positive | 3.7% | 18.8% | 19.5% |
| Max Negative | -6.7% | -5.0% | -15.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/28/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/13/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/29/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/28/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/13/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/29/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/17/2022 | 10-K |
| 09/30/2021 | 11/10/2021 | 10-Q |
Recent Forward Guidance
Updated 7/12/2026Latest: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2026 Phase 1 Recruitment Start for HWK-206 | |||||||
| 2026 IND Submission for HWK-206 | |||||||
| 2027 Initial Phase 1 Results for HWK-007 and HWK-016 | |||||||
Prior: Q4 2025 Earnings Reported 3/12/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2028 Cash Runway | Affirmed | Guidance: 2,028 for 2028 | |||||
Insider Activity
Updated 6/15/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Giacobello, Scott M | CHIEF FINANCIAL OFFICER | Direct | Sell | 4172026 | 4.13 | 141,600 | 584,808 | 1,219,275 | Form |
| 2 | Giacobello, Scott M | CHIEF FINANCIAL OFFICER | Direct | Sell | 4172026 | 3.86 | 77,000 | 297,220 | 1,686,141 | Form |
| 3 | Ball, Bryan | See remarks | Direct | Sell | 4152026 | 3.64 | 92,460 | 336,554 | 1,445,466 | Form |
| 4 | Ball, Bryan | See remarks | Direct | Sell | 4152026 | 3.46 | 26,389 | 91,306 | 1,693,898 | Form |
| 5 | Ball, Bryan | See remarks | Direct | Sell | 4132026 | 3.43 | 6,596 | 22,624 | 1,769,726 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Giacobello, Scott M | CHIEF FINANCIAL OFFICER | Direct | Sell | 4172026 | 4.13 | 141,600 | 584,808 | 1,219,275 | Form |
| 2 | Giacobello, Scott M | CHIEF FINANCIAL OFFICER | Direct | Sell | 4172026 | 3.86 | 77,000 | 297,220 | 1,686,141 | Form |
| 3 | Ball, Bryan | See remarks | Direct | Sell | 4152026 | 3.64 | 92,460 | 336,554 | 1,445,466 | Form |
| 4 | Ball, Bryan | See remarks | Direct | Sell | 4152026 | 3.46 | 26,389 | 91,306 | 1,693,898 | Form |
| 5 | Ball, Bryan | See remarks | Direct | Sell | 4132026 | 3.43 | 6,596 | 22,624 | 1,769,726 | Form |
| 6 | Ball, Bryan | See remarks | Direct | Sell | 4132026 | 3.57 | 50,000 | 178,500 | 1,865,507 | Form |
| 7 | Lennon, David James | CHIEF EXECUTIVE OFFICER | Direct | Sell | 4102026 | 3.38 | 14,500 | 49,010 | 1,752,942 | Form |
| 8 | Lennon, David James | CHIEF EXECUTIVE OFFICER | Direct | Sell | 4082026 | 3.40 | 63,945 | 217,413 | 1,812,615 | Form |
| 9 | Lennon, David James | CHIEF EXECUTIVE OFFICER | Direct | Sell | 4082026 | 3.43 | 94,087 | 322,718 | 2,047,940 | Form |
| 10 | Lennon, David James | CHIEF EXECUTIVE OFFICER | Direct | Sell | 4082026 | 3.51 | 102,395 | 359,406 | 2,425,951 | Form |
| 11 | Lennon, David James | CHIEF EXECUTIVE OFFICER | Direct | Sell | 4032026 | 3.48 | 26,858 | 93,466 | 2,761,551 | Form |
| 12 | Lennon, David James | CHIEF EXECUTIVE OFFICER | Direct | Sell | 3102026 | 3.31 | 5,100 | 16,879 | 147,539 | Form |
| 13 | Giacobello, Scott M | CHIEF FINANCIAL OFFICER | Direct | Sell | 3102026 | 3.31 | 2,594 | 8,585 | 93,000 | Form |
| 14 | Ball, Bryan | See remarks | Direct | Sell | 3102026 | 3.31 | 1,834 | 6,070 | 681,840 | Form |
Investor Activity (13F)
Updated Jul 17, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/16/2026